4D-150 - (4FRONT-2)

June 29, 2026: 4D Molecular Therapeutics (NASDAQ: FDMT) announced completion of global enrollment for 4FRONT-2, its second Phase 3 trial evaluating intravitreal 4D-150 in patients with wet age-related macular degeneration (wet AMD). The company said enrollment finished ~4 months ahead of projections and the trial over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026.

4FRONT-2 is a global, multicenter, randomized, double-masked, comparator-controlled study versus aflibercept 2 mg dosed every 8 weeks (Q8W). Primary endpoint is non-inferiority in mean change from baseline in best corrected visual acuity (BCVA) at 52 weeks; a key secondary endpoint is treatment-burden reduction based on the number of aflibercept injections in the 4D-150 arm vs comparator over 52 weeks (both arms may receive supplemental aflibercept).

Upcoming catalysts: 4FRONT-2 52-week topline data are expected in H2 2027; 4FRONT-1 (North America; similar design) 52-week topline data are expected in H1 2027. The company also stated it plans to initiate a Phase 3 trial of 4D-150 in diabetic macular edema (DME) in Q3 2026.